<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122650</url>
  </required_header>
  <id_info>
    <org_study_id>JZP385-201</org_study_id>
    <secondary_id>2020-002463-61</secondary_id>
    <nct_id>NCT05122650</nct_id>
  </id_info>
  <brief_title>A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)</brief_title>
  <official_title>A Phase 2b, 12-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter&#xD;
      study of the safety and efficacy of JZP385 in the treatment of adult participants with&#xD;
      moderate to severe ET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 17, 2021</start_date>
  <completion_date type="Anticipated">December 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of modified items 1 to 11 of the Tremor Research Group Essential Tremor Rating Assessment Scale - Activities of Daily Living (TETRAS-ADL) Subscale and modified items 6 and 7 of the TETRAS Performance Subscale (TETRAS-PS)</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>The TETRAS-ADL subscale is a patient-rated scale of the impact of tremor on day-to-day functioning administered by a trained interviewer. The TETRAS-ADL subscale directly measures how a patient functions by assessing activities impacted by tremor, such as eating and drinking, dressing and personal hygiene, carrying items, and fine motor skills. The TETRAS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs, and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. The TETRAS-PS is performed by a blinded rater at the site. Each item from the modified TETRAS-ADL and TETRAS-PS ranges from 0 to 3, with 0 representing normal or slightly abnormal and 3 representing severely abnormal. The sum of the individual scores provides the overall score, ranging from 0 to 42, with higher scores representing more severe ET.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the Clinical Global Impression - Severity scale CGI-S</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>The CGI-S is a 5-point Likert-type rating scale that a qualified medical personnel will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (no limitations) to 5 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reported as Much Improved on the Clinical Global Impression of Change (CGI-C)</measure>
    <time_frame>Week 12</time_frame>
    <description>The CGI-C is a 5-point Likert-type rating scale that a qualified medical personnel will use to rate the change in severity of the participants' ability to function due to their ET since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reported as Much Improved on the Patient Global Impression of Change (PGI-C) at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The PGI-C is a 5-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET since baseline. The responses to this scale range from 1 (Much improved) to 5 (Much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the TETRAS-ADL subscale as Summarized by Each Dose of JZP385 and Placebo</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>The TETRAS-ADL subscale is a patient-rated scale of the impact of tremor on day-to-day functioning administered by a trained interviewer. The TETRAS-ADL subscale directly measures how a patient functions by assessing activities impacted by tremor, such as eating and drinking, dressing and personal hygiene, carrying items, and fine motor skills. The TETRAS-ADL has 12 items and each item is rated on a 0 (normal) to 4 (severe) scale, with higher scores representing more severe ET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the TETRAS-PS Subscale as Summarized by Each Dose of JZP385 and Placebo</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>The TETRAS-PS is a clinical rating scale performed by a blinded rater that quantifies tremor in the head, face, voice, limbs, and trunk. Each item will be rated on a scale of 0 (normal) to 4 (severe). The sum of the individual scores provides the overall score, ranging from 0 to 64, with higher scores representing more severe ET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the Upper Limb Score (item 4) of the TETRAS-PS as Summarized by Each Dose of JZP385 and Placebo</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>Item 4 of the TETRAS-PS measures upper limb tremor, and includes 3 maneuvers for each arm that assess postural and kinetic tremor. Each item is rated on a scale of 0 (normal) to 4 (severe) in 0.5-point increments. The total score is the sum of each of the 6 items and ranges from 0 to 24, with higher scores representing more severe ET. The TETRAS-PS is performed by a blinded rater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the TETRAS Total Score, as Summarized by Each Dose of JZP385 and Placebo.</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>The TETRAS total score is the sum of the scores of the full TETRAS-ADL and TETRAS-PS subscales. Each item is rated on a 0 (normal) to 4 (severe) scale, and total scores range from 0 to 112, with higher scores representing more severe ET. The TETRAS-PS is performed by a blinded rater.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the Quality of Life in Essential Tremor Questionnaire (QUEST) as Summarized by Each Dose of JZP385 and Placebo</measure>
    <time_frame>Change from baseline to week 12</time_frame>
    <description>The Quality of Life in Essential Tremor Questionnaire (QUEST) was developed to specifically assess the impact of ET on health-related quality of life. The QUEST is a 30-item questionnaire comprising 5 subscales (physical, psychosocial, communication, hobbies/leisure, and work/finance) and a total score, plus 3 additional items relating to sexual function and satisfaction with tremor control and medication side effects. Each item is rated by frequency on a scale from 0 (never) to 4 (always), with higher scores indicating greater dissatisfaction or disability due to ET.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to Week 12 on the Essential Tremor Embarrassment Assessment (ETEA) as Summarized by Each Dose of JZP385 and Placebo</measure>
    <time_frame>Change from Baseline to Week 12</time_frame>
    <description>The Essential Tremor Embarrassment Assessment (ETEA) is a participant-rated questionnaire administered by a health care provider or researcher that contains 14-items assessing embarrassment related to tremor. Participants provide a simple response (disagree or agree) to each of the 14-items, the sum of which yields an initial score (Score A, range = 0 to 14). Participants then provide a more nuanced response to each question on a 0 to 5 point Likert scale ranging from disagree (0) to agree strongly (5). The sum of the nuanced responses yields a second score (Score B, range = 0 to 70). Higher scores on both the simple and nuanced responses indicate greater embarrassment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Moderate to Severe Essential Tremor</condition>
  <arm_group>
    <arm_group_label>10 milligram (mg) JZP385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will initially receive 5 mg/day from Day 1 through Day 7, and 10 mg/day starting on Day 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mg JZP385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, and 20 mg/day starting on Day 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg JZP385</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will initially receive 5 mg/day from Day 1 through Day 7, 10 mg/day from Day 8 through Day 14, 20 mg/day from Day 15 through Day 21, and 30 mg/day starting on Day 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo from Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JZP385</intervention_name>
    <description>JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.</description>
    <arm_group_label>10 milligram (mg) JZP385</arm_group_label>
    <arm_group_label>20 mg JZP385</arm_group_label>
    <arm_group_label>30 mg JZP385</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant must be 18 to 80 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          2. Participants who are diagnosed with ET (including ET plus) according to the MDS&#xD;
             Consensus Statement on the Classification of Tremors from the Task Force on Tremor of&#xD;
             the International Parkinson's and Movement Disorder Society.&#xD;
&#xD;
          3. Participants have moderate to severe disability associated with tremor as determined&#xD;
             by a score of â‰¥ 22 on the TETRAS-ADL subscale; and a score of &gt; 5 on the sum of items&#xD;
             6 and 7 of the TETRAS-PS; and a CGI-S rating of at least moderate for participants'&#xD;
             ability to function.&#xD;
&#xD;
          4. Sex and Contraceptive/Barrier Requirements&#xD;
&#xD;
        During the study intervention and for at least 30 days after the last dose of study&#xD;
        intervention male participants must refrain from donating sperm. Non-abstinent males must&#xD;
        agree to use a male condom in combination with female partner use of a highly effective&#xD;
        contraceptive method with a failure rate of &lt; 1% per year. All male participants must agree&#xD;
        to use a male condom when engaging in any activity that allows for passage of ejaculate to&#xD;
        another person.&#xD;
&#xD;
        Female participants must not be pregnant or breastfeeding, are either women of&#xD;
        non-childbearing potential (WONCBP), or are women of childbearing potential (WOCBP) using a&#xD;
        highly effective contraceptive method with a failure rate of &lt; 1% during the study&#xD;
        intervention period and for at least 30 days after the last dose of study intervention.&#xD;
        Male partners of WOCBP are required to use barrier protection, eg, condoms, over the same&#xD;
        30 day period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known history or current evidence of other medical or neurological conditions that may&#xD;
             cause or explain the participant's tremor.&#xD;
&#xD;
          2. Severe cognitive impairment as defined by a Montreal Cognitive Assessment (MoCA; score&#xD;
             &lt;23), or has cognitive impairment that in the opinion of the investigator would&#xD;
             prevent completion of study procedures or the ability to provide informed consent.&#xD;
&#xD;
          3. Current suicidal risk as determined from history, by presence of active suicidal&#xD;
             ideation as indicated by positive response to item 4 or 5 on the C-SSRS (within the&#xD;
             past 24 months), or any history of suicide attempt; current or past (within 1 year)&#xD;
             major depressive episode according to DSM-5 criteria.&#xD;
&#xD;
          4. History (within past 2 years at screening) or presence of substance use disorder&#xD;
             (including alcohol) according to DSM-5 criteria, known drug dependence, or seeking&#xD;
             treatment for alcohol or substance abuse related disorder. Nicotine use disorder is&#xD;
             excluded if it impacts tremor.&#xD;
&#xD;
          5. Prior magnetic resonance (MR)-guided focused ultrasound, surgical intervention (eg,&#xD;
             deep brain stimulation, ablative thalamotomy, gamma knife thalamotomy), or inability&#xD;
             to refrain from using a device for treatment of tremor for the duration of the&#xD;
             treatment period.&#xD;
&#xD;
          6. Botulinum toxin injection in the 6 months before screening or planned use at any time&#xD;
             during the study.&#xD;
&#xD;
          7. Treatment with any medication that could affect the evaluation of tremor within 2&#xD;
             weeks or 5 half-lives (whichever is longer) before screening or planned use at any&#xD;
             time during the study.&#xD;
&#xD;
          8. Use of prescription or nonprescription drugs or other products known to be inducers of&#xD;
             CYP3A4or CYP2C9, which cannot be discontinued at least 4 weeks before Baseline, or&#xD;
             planned use at any time during the study.&#xD;
&#xD;
          9. Use of prescription or nonprescription drugs, or other products (eg, grapefruit,&#xD;
             grapefruit juice, or Seville oranges) known to be strong or moderate inhibitors of&#xD;
             CYP3A4or CYP2C9, that cannot be discontinued 2 weeks or 5 half-lives, whichever is&#xD;
             longer, before Baseline or planned use at any time during the study.&#xD;
&#xD;
         10. Use of proton pump inhibitors and histamine-2 receptor antagonists, which cannot be&#xD;
             discontinued at least 2 weeks before Baseline, or planned use at any time during the&#xD;
             study (occasional use of antacids will be permitted, but antacids should be taken at&#xD;
             least 4 hours apart from study intervention).&#xD;
&#xD;
         11. Inability to refrain from use of medication/substance(s) that might produce tremor or&#xD;
             interfere with the evaluation of tremor on study visit days, such as, but not limited&#xD;
             to, stimulant decongestants, beta-agonist bronchodilators, and alcohol.&#xD;
&#xD;
         12. Regular use of more than 3 units of alcohol per day.&#xD;
&#xD;
         13. Regular consumption of caffeine &gt; 400 mg/day or &gt; 4 cups of coffee per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>215-832-3750</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Parkinson's Disease And Movement Disorder Center Of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Infinity Clinical Research, Llc</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Shore Neurology Associates, Inc.</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 2, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tremor</mesh_term>
    <mesh_term>Essential Tremor</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

